Please login to the form below

Not currently logged in
Email:
Password:

vitamin D

This page shows the latest vitamin D news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease

Until now, treating this disease has consisted of multiple daily doses of phosphate and vitamin D to counteract the effects of FGF23, a protein that when produced excessively, reduces renal phosphates

Latest news

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    Interestingly, the current standard of care consists of vitamin D supplements and oral phosphate – to boost low levels of phosphate found in the blood of XLH patients – but there is no

  • Shire finally bags EU approval for rare disease drug Natpar Shire finally bags EU approval for rare disease drug Natpar

    Shire's drug should only be used for patients who cannot be adequately controlled with standard therapy with calcium and vitamin D supplementation alone according to the EMA. ... and active vitamin D supplemental doses.

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    ahead for Natpara (parathyroid hormone), a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D.

  • A frugal future A frugal future

    Professor Brian D Smith is an authority on the pharmaceutical industry and works at SDA Bocconi University and Hertfordshire Business School. ... Or, in Homo sapiens, the evolution of pale skin as we moved out of Africa into higher latitudes with less

  • Relief for Shire as FDA clears NPS' Natpara Relief for Shire as FDA clears NPS' Natpara

    The US drugs regulator approved Natpara (recombinant parathyroid hormone) to treat low blood calcium levels - alongside calcium and vitamin D supplementation - in patients with the rare endocrine disease, which is caused ... This product offers an

More from news
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The relentless commitment to deals reflects the fall from grace of investment for in-house R&D. ... The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D

  • Deal Watch February 2016 Deal Watch February 2016

    Another route to divestment is to out-license drug candidates to new companies that can dedicate R&D resources to progress the development of those assets. ... investment. 42.5. ††† Rockwell Medical Technologies/ Wanbang Biopharmaceuticals. Triferic

  • Case study: Skin cancer awareness

    The credible back-story for Sunny-3 described it as a pharmaceutical treatment for winter vitamin D deficiency in northern latitudes.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The vitamin D deficiency: should we act?

    So we’re all at-risk of a vitamin D deficiency –but will we alter our lifestyles accordingly? ... It is presumed these delays were due to the huge wealth of ever-growing information regarding vitamin D.

  • When is sun safety doing more harm than good?

    We get most of our vitamin D from sunlight on our skin, and last year guidance from the  National Institute for Health and care Excellence (NICE)  said that  one in five ... Britons may now be deficient in vitamin D.

  • Say Communications

    The vitamin D deficiency: should we act?. ... Healthcare PR agency Say Communications analyses whether headlines are able to trigger a behavioural change with regards to the vitamin D deficiency issue.

  • Four Health Communications

    Fractyl; medical technology. Internis (UK); vitamin D. SEEK; biotechnology . Nordic Pharma; antibiotics, rheumatology.

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics